51 related articles for article (PubMed ID: 24159154)
1. Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime.
Grohs P; Kernéis S; Sabatier B; Lavollay M; Carbonnelle E; Rostane H; Souty C; Meyer G; Gutmann L; Mainardi JL
J Antimicrob Chemother; 2014 Mar; 69(3):786-9. PubMed ID: 24159154
[TBL] [Abstract][Full Text] [Related]
2. Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC Enterobacterales.
Hardy ME; Kenney RM; Tibbetts RJ; Shallal AB; Veve MP
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0082623. PubMed ID: 37882541
[TBL] [Abstract][Full Text] [Related]
3. The effects of switching from ceftriaxone to cefotaxime on the occurrence of third-generation cephalosporin-resistant Enterobacterales: A stepped-wedge cluster randomized trial.
Bouiller K; Gbaguidi-Haore H; Hocquet D; Crépin T; Wendling D; Borot S; Chirouze C; Bertrand X
Infect Dis Now; 2024 Feb; 54(1):104806. PubMed ID: 37838305
[TBL] [Abstract][Full Text] [Related]
4. Incorporating patient, nursing and environmental factors into antimicrobial stewardship: effects of simplifying treatment from cefuroxime to ceftriaxone.
Balm M; Bupha-Intr O; Sinha T; Kelly M; Stewart L; Stephen R; Blackmore T; Bloomfield M
N Z Med J; 2024 May; 137(1594):31-42. PubMed ID: 38696830
[TBL] [Abstract][Full Text] [Related]
5. Management of bacterial meningitis in adults.
Cohen J
BMJ; 2003 May; 326(7397):996-7. PubMed ID: 12742897
[No Abstract] [Full Text] [Related]
6. Comparing cefotaxime and ceftriaxone in combating meningitis through nose-to-brain delivery using bio/chemoinformatics tools.
Hathout RM; Abdelhamid SG; El-Housseiny GS; Metwally AA
Sci Rep; 2020 Dec; 10(1):21250. PubMed ID: 33277611
[TBL] [Abstract][Full Text] [Related]
7. An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam.
Gondane AA; Pawar DB
Cureus; 2023 Mar; 15(3):e36078. PubMed ID: 37056536
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic Stewardship in Treatment of Osteoarticular Infections Based on Local Epidemiology and Bacterial Growth Times.
Vidal P; Fourniols E; Junot H; Meloni C; Bleibtreu A; Aubry A
Microbiol Spectr; 2022 Dec; 10(6):e0143022. PubMed ID: 36377888
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Stewardship Program: Reducing Antibiotic's Spectrum of Activity Is not the Solution to Limit the Emergence of Multidrug-Resistant Bacteria.
Saliba R; Mizrahi A; Gauthier PP; Alban LM; Zahar JR; Pilmis B
Antibiotics (Basel); 2022 Jan; 11(1):. PubMed ID: 35052947
[TBL] [Abstract][Full Text] [Related]
10. Changes in antibiotic consumption, AMR and Clostridioides difficile infections in a large tertiary-care center following the implementation of institution-specific guidelines for antimicrobial therapy: A nine-year interrupted time series study.
Schönherr SG; Ranft D; Lippmann N; Lübbert C
PLoS One; 2021; 16(10):e0258690. PubMed ID: 34648594
[TBL] [Abstract][Full Text] [Related]
11. Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control.
Smith DR; Temime L; Opatowski L
Elife; 2021 Sep; 10():. PubMed ID: 34517942
[TBL] [Abstract][Full Text] [Related]
12. A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment.
Grégoire M; Berteau F; Bellouard R; Lebastard Q; Aubert P; Gonzales J; Javaudin F; Bessard A; Bemer P; Batard É; Lepelletier D; Neunlist M; Montassier E; Dailly É
Comput Struct Biotechnol J; 2021; 19():1423-1430. PubMed ID: 33777338
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review.
Pilmis B; Le Monnier A; Zahar JR
Microorganisms; 2020 Feb; 8(2):. PubMed ID: 32079318
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and the resistance mechanisms involved in
Druge S; Ruiz S; Vardon-Bounes F; Grare M; Labaste F; Seguin T; Fourcade O; Minville V; Conil JM; Georges B
J Intensive Care; 2019; 7():36. PubMed ID: 31360523
[TBL] [Abstract][Full Text] [Related]
15. Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.
Burdet C; Grall N; Linard M; Bridier-Nahmias A; Benhayoun M; Bourabha K; Magnan M; Clermont O; d'Humières C; Tenaillon O; Denamur E; Massias L; Tubiana S; Alavoine L; Andremont A; Mentré F; Duval X;
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936104
[TBL] [Abstract][Full Text] [Related]
16. Rationalizing antimicrobial therapy in the ICU: a narrative review.
Timsit JF; Bassetti M; Cremer O; Daikos G; de Waele J; Kallil A; Kipnis E; Kollef M; Laupland K; Paiva JA; Rodríguez-Baño J; Ruppé É; Salluh J; Taccone FS; Weiss E; Barbier F
Intensive Care Med; 2019 Feb; 45(2):172-189. PubMed ID: 30659311
[TBL] [Abstract][Full Text] [Related]
17. A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the intensive care unit.
Tan BK; Vivier E; Bouziad KA; Zahar JR; Pommier C; Parmeland L; Pariset C; Misslin P; Haond C; Poirié P; Temime L; Hocine MN
Intensive Care Med; 2018 May; 44(5):672-673. PubMed ID: 29396655
[No Abstract] [Full Text] [Related]
18. Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients.
de Lastours V; Goulenok T; Guérin F; Jacquier H; Eyma C; Chau F; Cattoir V; Fantin B
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):417-421. PubMed ID: 29318461
[TBL] [Abstract][Full Text] [Related]
19. Interventions to improve antibiotic prescribing practices for hospital inpatients.
Davey P; Marwick CA; Scott CL; Charani E; McNeil K; Brown E; Gould IM; Ramsay CR; Michie S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD003543. PubMed ID: 28178770
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
